---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-020335"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:14:30.822622+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed completes enrollment in Phase 2b neflamapimod trial for DLB; topline data due Dec 2024

## Summary
- Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB) fully enrolled.
- Topline data expected in December 2024 (16-week double-blind placebo-controlled period).
- Trial targets up to 160 patients; excludes AD co-pathology via plasma ptau181 screen (two-thirds eligible).
- Primary endpoint: Clinical Dementia Rating Sum of Boxes; funded by $21M NIH/NIA grant.
- 43 sites (32 US, 8 UK, 3 Netherlands) all initiated; open-label extension for 32 additional weeks.

## SEC filing metadata
- accession: 0001437749-24-020335
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924020335/0001437749-24-020335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924020335/crvo20240613_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-020335
- JSON: https://secwatch.observer/filing/0001437749-24-020335.json
- Plain text: https://secwatch.observer/filing/0001437749-24-020335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.